TherapeuticsMD
TXMD
41 hedge funds and large institutions have $11.7M invested in TherapeuticsMD in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 10 closing their positions.
75% more call options, than puts
Call options by funds: $517K | Put options by funds: $296K
3.81% less ownership
Funds ownership: 36.71% → 32.9% (-3.8%)
7% less funds holding
Funds holding: 44 → 41 (-3)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
40% less capital invested
Capital invested by funds: $19.4M → $11.7M (-$7.75M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Clearline Capital
New York
|
+$889K |
| 2 |
SSP
Sixth Street Partners
Dallas,
Texas
|
+$598K |
| 3 |
TC
Tejara Capital
London,
United Kingdom
|
+$184K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$71.2K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$38.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$2.71M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$398K |
| 3 |
PI
PEAK6 Investments
Chicago,
Illinois
|
-$224K |
| 4 |
Millennium Management
New York
|
-$111K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$75K |
TXMD Hedge Fund Activity: Q1 2023 in Review
41 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q1 2023, worth a combined $11.7M — down 40% from $19.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TXMD and 7 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Clearline Capital, adding an estimated $889K. The largest seller was Rubric Capital Management (New York), cutting an estimated $2.71M.
- 41 institutional investors held TherapeuticsMD (TXMD) as of Q1 2023, down from 44 in Q4 2022.
- Funds reported $11.7M of TherapeuticsMD stock for Q1 2023, down 40% quarter-over-quarter.
- 7 funds opened new TherapeuticsMD positions in Q1 2023 and 10 closed out, a net change of -3 holders.
- The largest TherapeuticsMD buyer in Q1 2023 was Clearline Capital, an estimated $889K added.
- The largest TherapeuticsMD seller in Q1 2023 was Rubric Capital Management (New York), an estimated $2.71M sold.
Based on aggregated 13F filings for Q1 2023.